Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
04/2003
04/03/2003WO2003026622A1 Lisinopril compositions having large-particle dcpd
04/03/2003WO2003026617A2 (ester)-lysolecithins in liposomes
04/03/2003WO2003026591A2 Modification of feeding behavior
04/03/2003WO2003026581A2 Pharmaceutical compositions and methods for treating cancer
04/03/2003WO2003026574A2 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
04/03/2003WO2003026570A2 Reduced toxicity cisplatin formulations and methods for using the same
04/03/2003WO2003026568A2 Androstanes as androgen receptor modulators
04/03/2003WO2003026564A2 Pharmaceutical compositions for the treatment of urinary disorders
04/03/2003WO2003026490A2 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
04/03/2003WO2003026479A2 Methods of suppressing microglial activation
04/03/2003WO2003002722A3 T cell regulatory genes and methods of use thereof
04/03/2003WO2003002531A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2003002530A3 Pyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2002102799A3 Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists
04/03/2003WO2002102766A3 Combretastatin a-3 prodrug
04/03/2003WO2002102313A3 Pyrimidine inhibitors of phosphodiesterase (pde) 7
04/03/2003WO2002100332A3 Isoxazoline compounds having mif antagonist activity
04/03/2003WO2002099052A3 Opns as modifiers of the p53 pathway and methods of use
04/03/2003WO2002099051A3 Nits as modifiers of the p53 pathway and methods of use
04/03/2003WO2002094270A3 Mip-1 alpha receptor ligands - drugs for t-cell mediated and autoimmune diseases
04/03/2003WO2002092563A3 Protease inhibitors
04/03/2003WO2002092016A3 Therapeutic use of rank antagonists
04/03/2003WO2002089729A3 Fused heterocyclic compounds
04/03/2003WO2002088336A3 Genetically modified yt cell line and use thereof
04/03/2003WO2002086078A3 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002057413A3 Peptides for activation and inhibition of delta pkc
04/03/2003WO2002056753A3 P27 prevents cellular migration
04/03/2003WO2002022166A9 Tweak receptor agonists as anti-angiogenic agents
04/03/2003WO2002014369A9 Human kininogen d5 domain polypeptides and their use
04/03/2003WO2002013846A3 Antifungal combination therapy
04/03/2003WO2002013808A3 Treatment of tumors with acetylenes distributed with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
04/03/2003WO2002010357A3 Gsk3 polypeptides
04/03/2003WO2002010214A3 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
04/03/2003WO2002000860A3 Novel proteases
04/03/2003WO2000038618A3 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
04/03/2003US20030065195 Ether compounds
04/03/2003US20030065186 Antihistamines, antiallergens, bronchodilator
04/03/2003US20030065179 Diabetic therapy
04/03/2003US20030065174 Antiinflammatory agents; analgesics
04/03/2003US20030065173 Therapy for drug abuse
04/03/2003US20030065151 Secreted protein HCEJQ69
04/03/2003US20030065146 Compound for use in the treatment of rheumatoid arthritis, osteoarthritis, inflammatory bowel disease and sepsis
04/03/2003US20030065137 Immunological methods to modulate myostatin in vertebrate subjects
04/03/2003US20030065040 Hypotensive agents
04/03/2003US20030065023 Anticancer agents, viricides, psychological disorders
04/03/2003US20030065018 Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
04/03/2003US20030065016 Nordihydroguaiartic derivatives for use in treatment of tumors
04/03/2003US20030065012 Estrogen receptor modulators
04/03/2003US20030065008 Hormone replacement therapy; side effect reduction
04/03/2003US20030065007 Analgesics; psychological disorders; antidepressants
04/03/2003US20030065004 Androgen receptor modulators and methods for use thereof
04/03/2003US20030064999 Therapy for asthma, diarrhea
04/03/2003US20030064996 Anticarcinogenic agents, antiinflammatory agents, anticholesterol agents, antidiabetic agents
04/03/2003US20030064993 Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
04/03/2003US20030064992 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
04/03/2003US20030064987 Immunology moderators; interleukin antagonist; anticancer agents
04/03/2003US20030064984 Anticancer agents; side effect reduction
04/03/2003US20030064983 Headaches; antiarthritic agents; respiratory system disorders; psychological disorders
04/03/2003US20030064973 Sexual disorders
04/03/2003US20030064944 Controlling cell differentiation, cell proliferation
04/03/2003US20030064943 High affinity TGFbeta nucleic acid ligands and inhibitors
04/03/2003US20030064942 Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
04/03/2003US20030064933 Transdermal administration of ACE inhibitors
04/03/2003US20030064929 Modulating body/cranial hair growth
04/03/2003US20030064928 Therapeutic preparations for inhalation
04/03/2003US20030064914 Copolymer-1 improvements in compositions of copolymers
04/03/2003US20030064510 Prevention or delaying apoptosis in recombinant cell; obtainceks transforme with nucleotide sequences coding antiapoptotic agents, express sequences, monitor adjustment in apotosis activity
04/03/2003US20030064509 Novel chromosomal vectors and uses thereof
04/03/2003US20030064493 Methods and means for modulating PGE synthase activity
04/03/2003US20030064431 Complement receptor type 1 (cr1)-like sequences
04/03/2003US20030064426 Expression vector for use in the treatment of cancer and age-related defects
04/03/2003US20030064410 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids
04/03/2003US20030064374 Detecting neuronal stress in humans; obtain sample, measure phosphodiesterase concentration, evaluate for neuronal stress
04/03/2003US20030064369 Novel proteins and nucleic acids encoding same
04/03/2003US20030064118 Combination of Ginseng and Ginkgo to improve cognitive skills
04/03/2003US20030064114 For vasodilatation and inhibition of transplant rejection
04/03/2003US20030064098 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
04/03/2003US20030064097 For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents
04/03/2003US20030064063 For prophylaxis of type I hypersensitivity disease in a subject receiving immunotherapy
04/03/2003US20030064052 Useful for maintaining controlled and reliable dosage of the therapeutic agent via pulmonary delivery
04/03/2003CA2820170A1 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
04/03/2003CA2463039A1 1,6-naphthyridine derivatives as antidiabetics
04/03/2003CA2461903A1 Monobactam antibacterial compounds and methods of use thereof
04/03/2003CA2461806A1 Water-soluble phenylpyridazine derivatives and medicines containing the same
04/03/2003CA2461801A1 Sphingolipids
04/03/2003CA2461731A1 Pharmaceutical compositions for the treatment of urinary disorders
04/03/2003CA2461709A1 Small organic molecule regulators of cell proliferation
04/03/2003CA2461631A1 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
04/03/2003CA2461603A1 Substituted amines for the treatment of neurological disorders
04/03/2003CA2461539A1 Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
04/03/2003CA2461532A1 Use of isogenic human cancer cells for high-throughput screening and drug discovery
04/03/2003CA2461504A1 Polymers with structure-defined functions
04/03/2003CA2461454A1 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
04/03/2003CA2461410A1 Dna providing system
04/03/2003CA2461363A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
04/03/2003CA2461360A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
04/03/2003CA2461345A1 Use of pyy or agonist thereof to modify feeding behaviour
04/03/2003CA2461305A1 Methods of suppressing microglial activation and systemic inflammatory responses
04/03/2003CA2461219A1 Reduced toxicity cisplatin formulations and methods for using the same
1 ... 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 ... 1564